Recorded Presentation from the NCCN Pharmacy Updates: Understanding the Place in Therapy for an Oral LHRH Antagonist as a Treatment Option in Prostate Cancer
Relugolix has a unique place in therapy for the treatment of prostate cancer. As a first-in-class oral LHRH antagonist, relugolix provides many benefits for patients. However, it is critical to understand how to manage the potential toxicities, drug interactions and adherence issues when initiating and maintaining this new oral agent.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Not Just a Band-Aid: The Impact of Chemotherapy Dose Banding in Infants
It is important for health care professionals caring for pediatric patients with cancer to identify challenges in chemotherapy dosing for infants and smaller children, rationales for current dosing recommendations commonly utilized in clinical trials, and the potential impact of BSA-based dose banding in this specific subset of the pediatric patient population.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Head and Neck Cancers, Version 1.2022
These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.
Category
  • Head and Neck Cancers
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Crossroads of Exercise and Chemotherapy
It is important to provide education and an action plan to outline how exercise may not only reduce side effects from chemotherapy but also help chemotherapy work better and improve survival. As new data emerges, more specific exercise “doses” can be prescribed.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Monthly Oncology Tumor Boards: Multidisciplinary Management of Localized Rectal Cancer
Trimodal therapy approaches for localized rectal cancer continue to evolve as new data helps define how to best improve outcomes while reducing adverse effects, with total neoadjuvant therapy among the approaches of recent interest. Clinicians can benefit from education on relevant clinical trial results related to trimodal therapy for localized rectal cancer and guidance on how these data may be best applied to clinical practice.
Category
  • Rectal Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date May 31, 2022
NCCN Pharmacy Updates: The Role of Tyrosine Kinase Inhibitors in Pediatric Acute Lymphoblastic Leukemia
It is important for health care professionals caring for pediatric patients with ALL to recognize aspects of optimal dosing and frequency, appropriate use in particular genomic alterations, mechanisms of resistance, and patient-specific counseling points to ensure efficacy and compliance of TKIs.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date August 24, 2022
TARGET FOR NSCLC: The Advancing Research into Genomic Pathways and use of EGFR Therapies
The goal of this initiative is to increase clinicians’ knowledge and improve their competence in understanding the latest advances in targeting genomic pathways for the treatment of non-small cell lung cancer (NSCLC) through a review of the current and ongoing research/clinical trials focused on
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: Advances in Multidisciplinary Management of Acute Myeloid Leukemia
Clinicians need to be informed about therapeutic advances and necessary supportive care precautions to aid in their effective and safe incorporation into clinical practice for the appropriate AML patient subpopulations.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: Systemic Therapy Selection in Metastatic Castration-Resistant Prostate Cancer
The selection of systemic treatments in various lines of therapy for patients with metastatic castration-resistant prostate cancer (CRPC) has become more and more complicated over the last several years. Clinicians who work with patients with metastatic CRPC need to be educated on these updates so that they can help their patients make optimal treatment choices across lines of therapy.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: Updates in Management of Renal Cell Carcinoma
Clinicians may find it difficult to determine which single- or multi-agent therapies are most effective for patients with different kidney cancer histologies and risk groups. The NCCN Categories of Preference and Categories of Evidence and Consensus help to stratify the most effective treatment regimens by histology and risk status.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation

Pages